Phase I safety, pharmacokinetic, and pharmacodynamic study of KW-0761 in CC chemokine-receptor 4 expressing peripheral T-cell lymphoma.
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Peripheral T-cell lymphoma; T cell lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 12 Dec 2011 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 12 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2008 Planned end date is 1 Dec 2009, according to clinicaltrials.gov.